Renal Anemia Clinical Trial
Official title:
A Phase III Trial to Compare the Safety and Efficacy of Intravenous UB-851 and Eprex® With an Extension Safety Evaluation in Subjects With Renal Anemia on Hemodialysis
The primary objective of this study is to evaluate a 1:1 dose conversion from Eprex® to UB-851 in terms of clinical efficacy and safety in subjects with chronic renal failure receiving hemodialysis.
This is a 52-week, phase III trial consisting of two parts: Part I is designed as a double-blind, randomized, multicenter, parallel-group study to evaluate the efficacy and safety of UB-851 in comparison to Eprex® in subjects with renal anemia on hemodialysis with a treatment period of 24 weeks. Part II is designed as a single-arm, safety evaluation period (from week 25 to week 52) to evaluate the long-term safety and immunogenicity of UB-851. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04925661 -
HEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia
|
Phase 1 | |
| Active, not recruiting |
NCT03388385 -
Acute Effects of Intravenous Iron on Oxidative Stress and Endothelial Dysfunction in Non-dialysis CKD
|
Phase 4 | |
| Completed |
NCT05035641 -
A Study of AND017 to Treat Anemia in Non-dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients
|
Phase 2 | |
| Completed |
NCT02299661 -
Pilot PK/PD Study of DS-1093a in Patients With Chronic Kidney Disease
|
Phase 1 | |
| Active, not recruiting |
NCT05265325 -
A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis
|
Phase 2 | |
| Completed |
NCT05864261 -
Pharmacokinetics Comparison Study of JT1801 and NESP® After Single Dose Administration in Chinese Health Male Volunteers
|
Phase 4 | |
| Active, not recruiting |
NCT05085275 -
Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease
|
Phase 3 | |
| Completed |
NCT02041208 -
Variability of Hemoglobin Levels After Kidney Transplantation
|
N/A | |
| Not yet recruiting |
NCT04775615 -
Multi-dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DDO-3055 Tablets in Healthy Subjects.
|
Phase 1 | |
| Completed |
NCT00298441 -
Efficacy of Intravenous Iron Administration in Hemodialysis Patients
|
Phase 4 | |
| Active, not recruiting |
NCT04408820 -
Post-marketing Surveillance of EVRENZO® Tablets (Roxadustat) in Patients With Renal Anemia
|
||
| Completed |
NCT01543477 -
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia
|
||
| Completed |
NCT05951192 -
A Prospective Interventional Study Assessing the Clinical and Operational Effectiveness of Transitioning From Mircera to Daprodustat for the Treatment of Anemia in End Stage Kidney Disease
|
Phase 4 | |
| Completed |
NCT04454879 -
Different Doses of Roxadustat Treatment for Anemia in Peritoneal Dialysis Patients
|
Phase 4 | |
| Recruiting |
NCT04360902 -
Assessment of an Anemia Model Predictive Controller for Anemia Management in Hemodialysis Patients
|
N/A | |
| Not yet recruiting |
NCT03480178 -
Renal Anemia Refractory to Erythropoietin
|
||
| Completed |
NCT01306409 -
Neocytolysis in the Treatment of Renal Anemia With Erythropoieses Stimulating Agents (ESA)
|
Phase 4 | |
| Completed |
NCT00322413 -
Comparison of Epoetin Alfa and Epoetin Omega in Anemic Dialysis Patients:Results of Efficacy Trial
|
Phase 3 | |
| Recruiting |
NCT05970172 -
A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease
|
Phase 3 | |
| Completed |
NCT02947438 -
Biosimilar Erythropoietin in Anaemia Treatment (Maintenance Phase Study)
|
Phase 3 |